SEASTAR MEDICAL HOLDING CORPORATION - COMMON STOCK

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

25 أكتوبر 2024 10:32:00 بحسب Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

25 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

23 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

18 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

15 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

09 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

08 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

25 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

05 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt

04 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update

13 أغسطس 2024 15:38:00 بحسب Nasdaq GlobeNewswire

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

23 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

16 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner

12 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

11 يوليو 2024 15:05:00 بحسب Nasdaq GlobeNewswire